Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for December 2011
December 1, 2011
- Dismay at NICE's Gilenya Decision
- Digitas Head Moves to Head Time Inc.
- AVEO Pharmaceuticals and Boehringer Ingelheim Announce Manufacturing Agreement for Ficlatuzumab
- Lilly Announces First and Only International, Prospective Observational Study Designed to Understand Barriers to Progression of Insulin Treatment
- Regulatory Update: Glaxosmithkline Submits Additional Information for Candidate Meningococcal and Hib Combination Vaccine
- NICE - MS drug not cost effective, says latest draft guidance
- Takeda Pharmaceutical Company Limited Overflow of Contaminated Water at Shonan Research Center
- A New Era in Pharmaceutical Innovation Means Major Challenges for the Industry
- Gerbig, Snell/Weisheimer & Associates (GSW) Co-Founder Bob Gerbig Dies
- Teva Announces Tentative Approval of Generic Lipitor
December 2, 2011
- Bristol-Myers Squibb Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals for Phase II Combination Study in Patients Chronically Infected with Hepatitis C
- Pfizer Completes Acquisition of Excaliard
- Baucus, Grassley, Kohl Examine Pharmaceutical Deals that Limit Access to Generic Drugs
- AO Testimony on Oversight of Psychotropic Prescriptions for Children in Foster Care
- Synthes CEO to Get $52M in Company Sale
- Eisai Announces Commencement of Operations of a New Research Facility at H3 Biomedicine Inc., a U.S. Research Subsidiary to Facilitate Cutting-Edge Cancer Genomics-Driven Drug Development
- Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
- US Report: Foster Kids Get High Rate of Psych Meds
- Senators Demand Pfizer Documents on Lipitor Deals
December 5, 2011
- Groundbreaking Scientific Collaboration Gives UK Academia Access to Compounds to Advance Medical Research
- Unigene Regains Exclusive Worldwide Rights of Oral PTH from GSK
- Takeda to Launch Global Vaccine Business Company to establish Vaccine Business Division and Appoints Dr. Rajeev Venkayya as its Leader
- The Carlyle Group and Hellman & Friedman Complete Acquisition of PPD
December 6, 2011
- New Study Finds European Consumers Show Considerable Interest in Learning from Pharma Companies ? But Not on Facebook or Twitter
- Genmab Announces Appeal of US Court Judgment in Favor of Arzerra in Patent Infringement Lawsuit
- UK Leader Wants Health Service to Help Industry
- Former Pfizer Employee Gets Suspended Sentence for eBay Scam
- Two Kinds of the Pill Raise Blood Clot Risk More Than Others: Health Canada
- How A Little-Known Drug Posed A Big FDA Dilemma
- Merck Establishes New MSD R&D Asia Headquarters
- Ranbaxy Launches Version of Pfizer's Caduet
December 7, 2011
- Certain Medications Used for Diseases Such as Rheumatoid Arthritis Not Associated With Increased Risk of Hospitalization For Serious Infections
- FDA Favors More Risk Info on Birth Control Pills
- FDA Announces Changes to Risk Strategy Requirements for Two Drugs to Treat Low Platelet Counts
- A Dendreon Sells Victrelis Royalty Rights for $125M
- Bill Would Make Drug Price Gouging A Federal Crime
- Amgen and FDA Agree to Modify Nplate (Romiplostim) Risk Evaluation and Mitigation Strategy
- Phila. Jury Orders Pfizer to Pay 3 Women $72.6 Million in Damages Over Menopause Drugs
- FDA Warns Novartis on 3 Manufacturing Facility Sites
- Topotarget Announces Reorganization Plans
- Protalix Plunges As FDA Postpones Gaucher's Approval
- Theratechnologies to discontinue COPD clinical program and accelerate path to profitability
- AstraZeneca to Streamline US Sales Organization
- Statement from FDA Commissioner Margaret Hamburg, M.D. on Plan B One-Step
December 8, 2011
- FDA Moves Pfizer Drug a Step Closer to Approval
- U.S. Nixes Easy Access To Morning-After Pill
- Auxilium Pharmaceuticals, Inc. Appoints Adrian Adams Chief Executive Officer and President
- Amgen Announces Preliminary Results of Its Tender Offer
- AstraZeneca to acquire generics company to broaden patient access to medicines in China
- FDA Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate)
- Amgen Expects to Acquire 83.3M Shares in Buyback
December 9, 2011
- Bayer's Drospirenone-containing Combination Oral Contraceptives: FDA Advisory Committees Affirm Positive Benefit-risk Profile and Recommend an Update of Labels to Reflect Information From Available Studies
- Auxilium Pharmaceuticals Gets New CEO
- Companies, NIH Unite to Provide Chemical Database
- Pharmacyclics Could Get $975M in J&J License Deal
- FDA Panel Wants More Risk Information on Yaz Pills
- IRS Wants $581 Million More From Boston Scientific
- DAIICHI SANKYO -About the News Report
- FDA Finds Serious Problems in Cancer Drug Factory
December 12, 2011
- ICON Acquires BeijingWits Medical Consulting Ltd
- Icon Buys Chinese Clinical Research Firm
- Teva Wins Appeal on Cephalon Drug
- Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Next-Generation Antioxidant Inflammation Modulators
- Pfizer Elects CEO Ian Read As Chairman Of The Board
December 13, 2011
- Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
- Quintiles Launches China CRO, Kun Tuo
- SEC Charges GlaxoSmithKline Subsidiary and Former CEO With Defrauding Employees in Stock Plan
- Novartis Preparing for Pandemic
December 14, 2011
- Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound
- Negligible generic Lipitor sales for Teva - report
- Bisphosphonate Antiresorptive Agent, Ibandronate Sodium Hydrate Injection, Demonstrates Efficacy in Osteoporosis in Phase II/III Trial
- Boehringer Ingelheim significantly expands its supply center for China
- Premiere Cooperative Group in Adult Lymphoma Research (GELA) Chooses REVLIMID for Study in Second Most Common Lymphoma Subtype
- CEO says Genzyme ready to roll
- Novartis investigating MS patient's death
- Synovis to be acquired for $325M
- Salix Submits FDA application for Crofelemer
December 15, 2011
- Isis Adds Three New Drugs to Its Development Pipeline
- Isis Updates Kynamro Submission Timeline
- Eli Lilly Ends Agreement With TransPharma
- Viropharma's Antibiotic Vancocin Gets New Label
- Amgen Completes $5B Share Buyback
- Changes to the Roche Corporate Executive Committee
- FDA Sends Letter to NeurogesX Over Exhibit Booth
- FDA Sends Letter to Sunovion Regarding Sales Rep Pitch
- FDA Sends Letter to EUSA Pharma Regarding Kit Risks
- BioSante Female Sex Drug Fails in 2 Studies
- Amsterdam Molecular Therapeutics Announces Negative Equity Position
- Takeda and Affymax Provide Update on Peginesatide Commercialization Rights in Japan
- Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
December 16, 2011
- FDA Supports Bennet Call to Address Prescription Drug Shortage, Improve Safety With Universal System
- Gilead Seeks First-Ever Approval for Drug to Prevent HIV
- Pfizer, Glaxo Expand Discount Vaccine Agreements
- Novartis Says MS Drug Gilenya Met Goals in Study
- Valeant Makes Hostile Bid for ISTA Pharmaceuticals
- Kevin Sharer Out As Amgen CEO
December 19, 2011
- Suit Against Thalidomide Maker Set for Australia
- Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
- Somaxon Pharmaceuticals Hires Financial Advisor to Assist in Seeking Strategic Alternatives
- ALS Therapy Development Institute Announces Research Agreement with Biogen Idec and UCB to Investigate the Role of CD40L in ALS
- Amgen Rises After Announcing Retirement of CEO
- Bayer's Xarelto (rivaroxaban) Becomes First Fixed Dose Once-Daily Anticoagulant Tablet Approved in the UK for Stroke Prevention in non-valvular Atrial Fibrillation; and the First Single Drug Regimen for Deep Vein Thrombosis
- Cegedim Strategic Data (CSD) Ranks Pharmaceutical Companies' Social Media Presence
- GSK Looking to Aggressively Expand in Pakistan
- Alexza Retains Lazard to Explore Strategic Options
December 20, 2011
- Man Gets 13 Months in Fake-pill Ring
- Alcon to Move about 400 Employees to Ex-hotel Site
- Genzyme Details Late-Stage Trial of MS Treatment
- Novartis Announces Termination of ALTITUDE Study With Rasilez/ Tekturna in High-Risk Patients With Diabetes and Renal Impairment
- Multaq (dronedarone): Drug Safety Communication - Increased Risk of Death or Serious Cardiovascular Events
- HIV/AIDS Update - Updated Information About Prezista (Darunavir): Oral Suspension and Labeling Changes
- ImmunoGen, Inc. Announces Antibody-Drug Conjugate Collaboration With Lilly
- AstraZeneca Drops 2.5% After Drug Failures and Write-Off, but FTSE Struggles for Direction
- Teva in Talks to Sell Part of Cephalon Unit
- FDA Adds New Heart Warning to Sanofi's Multaq
- With New Generic Rivals, Lipitor's Sales Halved
- Eli Lilly, Immunogen Enter Drug Development Deal
- Amgen, Watson Partner on 'Biosimilar' Cancer Drugs
December 21, 2011
- FDA Drug Safety Communication: Safety Review of a Reported Death after the First Dose of Multiple Sclerosis Drug Gilenya (fingolimod)
- Lawsuit over Inflated Drug Prices Ends, AG Coakley Recovers $47 Million for Medicaid Program
- Ranbaxy Settles with FDA over Manufacturing
- Antares Announces Licensing deal with Pfizer
- Zogenix and Astellas Agree to End Co-Promotion for Sumavel DosePro Effective March 31, 2012
- GlaxoSmithKline Provides Update on Divestment of non-core over-the-counter (OTC) brands
- Takeda to Acquire Intellikine, Adding Two Novel Programs to its Oncology Pipeline
- Establishment of Takeda California, Inc. by Integration of Takeda San Diego, Inc. and Takeda San Francisco, Inc.
- AstraZeneca Enters into Option Agreement to Acquire New Class of Diabetes Assets from Prosidion
- Ranbaxy to Market Daiichi Sankyo?s Innovative Products in Malaysia
December 22, 2011
- Vivus: Qnexa Ingredient Linked to Birth Defects
- Dr. Rob Koremans to succeed Dr. Gerard van Odijk as President and CEO of Teva Europe
- Spartanburg Judge Upholds $327M Verdict Against Pharmaceutical Company
- FDA Approves Merck HIV Drug for Children
- Valeant Pharmaceuticals Completes Acquisition of iNova
- Abbott Initiates Clinical Trial to Study Drug Eluting Bioresorbable Therapy for Treatment of Peripheral Artery Disease
- Takeda and MSD mutually agree to end co-promotion agreement for Daxas
- Poniard Pharmaceuticals and Allozyne Terminate Planned Merger
- Lundbeck Divests Several Products in the US As Part of Long-Term Business Strategy
- Baxter and Momenta Announce Collaboration to Develop and Commercialize Follow-On Biologics
- AMRI Announces Additional Actions to Streamline Operations
December 25, 2011
December 27, 2011
- Mylan Receives Approval for First-to-File Generic Keppra XR Extended-Release Tablets
- India Tycoon's Got Tons of Cash, Nowhere to Invest
- Forma Therapeutics Teams Up With Giants in Cancer Fight
- Contract Pharmaceuticals Closes Plant
- Albany Molecular Silent on Job Cuts at U.S. Operations
December 28, 2011
- New Painkiller Worries Experts
- Immunomedics and UCB Announce Restructuring of Epratuzumab License Agreement
- Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with Abbott
- Priorities, Staffing Impede Inspections of Drug, Device Makers
- Alnylam Announces Publication of Pre-clinical Results with ALN-HTT, an RNAi Therapeutic for the Treatment of Huntington's Disease, in Experimental Neurology
- Meridian Says FDA Clears New Bacterial Test
- FDA Alerts Pharmacists and Health Care Professionals to Potential for Injury when Dispensing the Similar-Sounding Drugs Durezol and Durasal
December 29, 2011
- Pharmaceutical Firm to Pay $30M Settlement in False Claims Suit
- Pfizer's Offer of Discount Lipitor Prompts Outcry
- Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP)
- Bristol-Myers Squibb to Expand Activity in Israel
- Alexion Pharma to Buy Enobia for Up to $1.08B
- No Co-Pay Pays Off for Pharma Firms
- China Sky One Medical Announces Resignation of its Chief Financial Officer
- Company Admits Missteps in Drug Testing
- 2011: An Uncomfortable Year for India's Pharmaceutical Sector
